SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Odyssey Therapeutics Reports Third-Quarter 2026 Results and Clinical Update

The company said additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof.

ODTX

Related stories